GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » YoY EBITDA Growth

Telix Pharmaceuticals (Telix Pharmaceuticals) YoY EBITDA Growth : 217.02% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Telix Pharmaceuticals YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Telix Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 217.02%.

Telix Pharmaceuticals's EBITDA per Share for the six months ended in Dec. 2023 was $0.06.

Telix Pharmaceuticals YoY EBITDA Growth Historical Data

The historical data trend for Telix Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals YoY EBITDA Growth Chart

Telix Pharmaceuticals Annual Data
Trend Sep99 Sep00 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only -28.57 -70.83 -44.72 -6.18 125.40

Telix Pharmaceuticals Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.95 -97.33 56.48 95.27 217.02

Telix Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Telix Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(0.048--0.189)/ | -0.189 |
=125.40 %

Telix Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (Q: Dec. 2023 )
=(EBITDA per Share (Q: Dec. 2023 )-EBITDA per Share (Q: Dec. 2022 )) / | EBITDA per Share (Q: Dec. 2022 )) |
=(0.055--0.047)/ | -0.047 |
=217.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telix Pharmaceuticals YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Telix Pharmaceuticals (Telix Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » YoY EBITDA Growth
Comparable Companies
ASX:NEU ASX:CUV ASX:IMM ASX:IMU ASX:MSB ASX:CU6 ASX:PYC ASX:OPT ASX:BOT ASX:PAR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
TLX:Australia
Address
55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051
Website
https://www.telixpharma.com
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.